Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Bariatric Surgery and Outcomes, Diabetes Treatment and Management, Pituitary Gland Disorders and Treatments, and Adrenal and Paraganglionic Tumors.
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update.
Dose Equivalence across GLP-1 Receptor Agonists: A Dose Response Meta-Analysis and Digital Tool Development
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO)
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
European Association for the Study of Obesity Position Statement on the Diagnosis and Management of Obesity in Older Adults
Tirzepatide and the NHS: are we creating a two-tier obesity treatment system?
Culturally Tailored Diabetes Self-Management Education and Support Programs in Black African and Caribbean Adults With Type 2 Diabetes (HEAL-D): Protocol for a Multicenter, Pragmatic Randomized Controlled Trial.
Culturally Tailored Diabetes Self-Management Education and Support Programs in Black African and Caribbean Adults With Type 2 Diabetes (HEAL-D): Protocol for a Multicenter, Pragmatic Randomized Controlled Trial (Preprint)
Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial
Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia
Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia.
Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis.
Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.
Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial.
Impact of BMI and comorbidities on efficacy of once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial.
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
Changing the narrative around obesity in the UK: a survey of people with obesity and healthcare professionals from the ACTION-IO study.
A systematic review of randomized controlled trials of dietary interventions for weight loss in adults in the Middle East and north Africa region.
Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery.
Low-energy total diet replacement intervention in patients with type 2 diabetes mellitus and obesity treated with insulin: a randomized trial.
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial.
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.